Valuation Strategy
How Smart Founders Calculate Valuation in MedTech and Deep Tech (When Revenue Is Still a Dream)
In MedTech and Deep Tech, traditional SaaS benchmarks don’t apply. Valuation isn’t about revenue—it’s about risk. Here’s how the best founders justify value through milestone-based de-risking.
Here’s a secret most early-stage founders never hear:
In MedTech and Deep Tech, you don’t raise on revenue. You raise on de-risking.
Investors aren’t just betting on your traction today.
They’re betting on your ability to clear highly specific technical, clinical, and regulatory hurdles—fast enough to surviveand deliver a return.
If you’re trying to raise a Seed or Pre-Seed round with no revenue, no problem—as long as you understand what valuation is actually based on.
Valuation Is a Reflection of Risk — Not Revenue
Forget applying SaaS-style revenue multiples.
Forget capping your SAFE at a random number because “someone said it’s market.”
Your valuation is a direct function of your risk profile—and how much of that risk you’ve already removed.
Here’s what real valuation step-ups are built on:
• Proof of Concept or Prototype Validation
(Can you show that your core tech actually works?)
• Regulatory Progress
(Are you on track for 510(k), De Novo, CE Mark, or relevant approvals?)
• Clinical or Preclinical Data
(Have you published results or begun early-stage trials?)
• First Commercial Signals
(Letters of intent, pilots, early revenue—even before full-scale launch)
• Strategic Partnerships
(Distribution, manufacturing, or co-development deals that validate your GTM plan)
Each of these milestones de-risks the business—and gives you a credible reason to ask for a higher valuation.
The Early-Stage Valuation Formula (Simplified)
Here’s a back-of-the-napkin way to think about how early-stage investors approach valuation:
Valuation = (Estimated Exit Value) × (Probability of Success) ÷ (Investor Return Multiple)
Let’s break it down with a real example:
• Target Exit Value: $150M
• Probability of Success: 10% (typical for deep tech or medtech)
• Target Return Multiple: 10x for early-stage capital
($150M × 0.10) ÷ 10 = $1.5M post-money valuation
That may seem low—but it’s grounded in math, not emotion.
Now, if you hit a key milestone (say, 510(k) clearance or a $1M distribution LOI), your probability of success might jump from 10% to 20% or more. And that doubles your valuation overnight.
Translation: You’re not just building product. You’re building confidence.
What to Avoid: Common Valuation Mistakes
• Copying SaaS multiples:
MedTech and DeepTech require different risk-adjusted models.
• Ignoring regulatory timelines:
You can’t fake speed in regulated industries.
• Assuming IP = value:
Without a path to market, even the best patents are just paper.
• Overreaching too early:
Ask for a $10M valuation without matching milestones, and you’ll scare off the smart capital.
The Real Purpose of Early Capital
Every dollar you raise early on is about buying time to prove something.
Whether that’s:
• Clinical feasibility
• Initial customer adoption
• Regulatory clarity
• Repeatable go-to-market motion
Your job is to frame your raise as a bridge to the next de-risked milestone—and show how crossing that bridge justifies the next valuation step.
Bottom Line:
In MedTech and Deep Tech, traction looks different.
The winners raise smart, de-risk hard, and build real value - not just hype.
If you want investors to take your valuation seriously, you have to show them why it’s real, and what you’re solving next.
Want Help Validating Your Valuation Strategy?
At The Scale Foundry, we work with founders in deep tech, healthtech, and regulated industries to clarify milestones, model credible valuation ranges, and build investor confidence at every stage.
Explore Capital Advisory Services